The first (experimental) problem that has been clearly identified recently is that most of the AD models used in experimental studies are not clinically valid and therefore cannot be adequately translated into the clinic
Beneficiaries who already receive a GLP-1 through their Part D plan for a covered Medicare indication such as type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea will continue accessing the drug through their regular Part D plan rather than through the Bridge
Evidence can be limited, mixed, preclinical, observational, old, formulation-specific, or otherwise insufficient to support an FDA-approved indication
Semaglutide had cardioprotective effects in T2DM patients
However, its essential to consult with a healthcare provider to determine the most appropriate schedule for your specific situation